Management of Moderate to Severe Ulcerative Colitis: Treatment Approaches

Released On
November 13, 2020

Expires On
November 12, 2021

Media Type

Completion Time
30 minutes

Gastroenterology, Immunology, Primary Care

Ulcerative Colitis, IBD, Inflammatory Bowel Disease

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by the American Gastroenterological Association in collaboration with Clinical Care Options, LLC.


This activity is supported by an educational grant from Pfizer Inc.

Credit Available

  • Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)
  • Nurses — 0.5 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

The primary target audience for this activity includes gastroenterologists, nurses, nurse practitioners, and other healthcare providers who treat patients with ulcerative colitis.

Program Overview

The goal of this activity is to improve clinicians’ competence to select effective treatment for patients with moderate to severe ulcerative colitis, including those with difficult-to-treat UC who have failed TNF inhibitor therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recommendations from the latest UC management guidelines regarding next steps for patients with moderate to severely active UC
  • Consider the utility of the latest UC therapies that can better align with patients’ needs for a treatment that is convenient, effective, and safe



Anita Afzali, MD, MPH, FACG

Associate Professor of Medicine
Medical Director, OSU Inflammatory Bowel Disease Center
Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease
Division of Gastroenterology, Hepatology and Nutrition
The Ohio State University Wexner Medical Center
Columbus, Ohio


Millie D. Long, MD, MPH

Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Physician Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

The AGA Institute designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Disclosures of Conflicts of Interest

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Anita Afzali, MD, MPH, FACG

  • Consulting Fees: AbbVie, Celgene/Bristol-Myers Squibb, Janssen, Pfizer, and Takeda
  • Research Support: AbbVie, Celgene/Bristol-Myers Squibb, Janssen, Lilly, and Takeda
  • Fees for non-CME/CE Services: AbbVie, Janssen, Pfizer, and Takeda
  • Other Financial Material Support : IBD Horizons.

Millie D. Long, MD, MPH

  • Consulting Fees: AbbVie, Gilead Sciences, Janssen, Pfizer, Prometheus, Salix, Target PharmaSolutions, UCB, and Valeant
  • Research Support: Pfizer and Takeda.


Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Anne Roc, PhD, has no relevant conflicts of interest to report.

David Howard, PharmD, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 13, 2020, through November 12, 2021:

  1. Register online at
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. Study the educational activity online or printed out.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Site Viewing Requirements

  • Web browsers: Latest versions of Edge, Internet Explorer, Chrome, Firefox, and Safari
  • Mobile devices: Latest versions of Android and iOS
  • JavaScript Enabled. This website requires JavaScript to be enabled in your browser. To enable JavaScript, click here.
  • Cookie Enabled. This website requires cookies to be enabled in your browser. To enable cookies, click here.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

For CME questions please contact: